Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 5Leukemia, Lymphocytic, Chronic, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Prolymphocytic 3Breast Neoplasms 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1

Interventions

Paclitaxel 2Kidney Transplantation 2Cyclophosphamide 2Azacitidine 2veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pomalidomide 1pevonedistat 1osimertinib 1mirabegron 1glucarpidase 1gamma-Glutamyl Hydrolase 1dabrafenib 1copanlisib 1belinostat 1belantamab mafodotin 1Whole-Body Irradiation 1Topotecan 1Taxes 1Sitagliptin Phosphate 1Rituximab 1Pharmacogenomic Testing 1Oxaliplatin 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Renal Insufficiency × Pharmacogenomic Testing × Clear all
NCT01907802 2018-08-14

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Terminated
8 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡